^
12d
SHR0302 and Steroid As First Line Therapy for Chronic GVHD (clinicaltrials.gov)
P1, N=28, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | N=73 --> 28 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Sep 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
prednisone • ivarmacitinib (SHR0302)
3ms
Enrollment open
|
SHR-2554 • ivarmacitinib (SHR0302)
4ms
New P2 trial
|
SHR-2554 • ivarmacitinib (SHR0302)
9ms
A SHR0302 BA Study on Healthy Subjects (clinicaltrials.gov)
P1, N=16, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Active, not recruiting
Enrollment closed
|
ivarmacitinib (SHR0302)
9ms
SHR0302 and Steroid as First Line Therapy for Chronic GVHD (clinicaltrials.gov)
P1, N=73, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Jul 2023 --> Jul 2024
Trial primary completion date
|
prednisone • ivarmacitinib (SHR0302)
11ms
A SHR0302 BA Study on Healthy Subjects (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P1 trial
|
ivarmacitinib (SHR0302)
12ms
To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability (clinicaltrials.gov)
P1, N=16, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
Trial completion
|
ivarmacitinib (SHR0302)
1year
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis (clinicaltrials.gov)
P3, N=566, Completed, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: May 2022 --> Jan 2023
Trial completion • Trial completion date • Trial primary completion date
|
ivarmacitinib (SHR0302)
1year
A Novel JAK1 Inhibitor SHR0302 for Treatment of Chronic Graft-Verse-Host Disease: A Phase I Clinical Trial (ASH 2023)
In summary, SHR0302 in combination with prednisone had a good safety and could achieve a high response for naïve-treatment cGVHD, which suggests that SHR0302 combination might become an optimal choice for naïve-treatment cGVHD.
Clinical • P1 data
|
prednisone • ivarmacitinib (SHR0302)
over1year
New P1 trial
|
ivarmacitinib (SHR0302)
over1year
Clinical • P2 data • Journal
|
CD8 (cluster of differentiation 8) • JAK1 (Janus Kinase 1)
|
ivarmacitinib (SHR0302)